Medlander (南京麦澜德医疗科技)

Medlander operates in medical devices and health diagnostics, with a focused specialization in pelvic-floor assessment and treatment. Its described portfolio covers multiple stages of care: surface electromyography for evaluation, color Doppler ultrasound for pelvic and gynecological imaging, and rehabilitation devices using magnetic stimulation, biofeedback, focused-energy ultrasound, and electrocautery. That breadth suggests a combined diagnostic-and-treatment offering rather than a single-device focus, while the company description also emphasizes software integration and clinical workflow efficiency. Its market position is therefore best characterized by specialty and product scope, not an unsupported claim of category leadership. The company is based in Nanjing and is listed in the Health Care, Health Diagnostics, and Medical categories.

Medlander’s disclosed financing chronology begins with a CNY 3 million Angel round on Dec 7, 2018, followed by a CNY 10 million Series A on Dec 2, 2019, with Greenwoods Asset Management identified as the Series A lead. A separate entry records an IPO on Aug 8, 2022 and a CNY 1,007.25 million amount, but this conflicts with the structured company funding total of approximately $1.86 million and with a private-company status field. The IPO entry is therefore a significant but unverified inflection point rather than a basis for revising the preferred total-funding figure. The product set indicates development across diagnostic imaging, surface electromyography, magnetic stimulation, ultrasound rehabilitation, biofeedback, and electrocautery. Current employee size is placed in the 11–50 range, and hiring information describes continued recruitment and talent development without role-level detail. A Jun 5, 2026 investment in Zhimei Keji signals an investment activity outside Medlander’s own financing history; its stated CNY 200 million is the investee’s round size.